Investment Newsletters

JP Morgan

UPDATE: J.P. Morgan Maintains Overweight On Gilead Sciences As It Strikes Exclusive HCV Deal With CVS

In a research report sent to investors a short while ago, J.P.

Ben Mahaney, Editor — January 5, 2015, 3:27 PM EDT

J.P. Morgan Remains On The Sidelines On Celgene; Waits For Additional Drivers Of Near-Term Upside

In a research report published today, J.P.

Ben Mahaney, Editor — January 5, 2015, 3:06 PM EDT

J.P. Morgan Provides Key Thoughts On Regeneron Heading Into 2015

In a research report sent to investors today, J.P.

Jason Cohen — January 5, 2015, 2:41 PM EDT

We See Potential For Additional Meaningful Upside In Vertex, Says J.P. Morgan

In a research note sent to investors today, J.P.

Ben Mahaney, Editor — January 5, 2015, 2:29 PM EDT

UBS Downgrades JP Morgan To Neutral; Sees No Sufficient Upside To PT

In a research report released today, UBS analyst Brennan Hawken downgraded shares of JP Morgan (NYSE:JPM) to a Neutral rating from a Buy …

Editor Ben Weinberg — October 2, 2014, 7:33 PM EDT

« 1 2